BioVector? MUG-Lucifer-met 人骨肉瘤細(xì)胞系 / MUG-Lucifer-met Human Osteosarcoma Cell Line

通用定義 / General Definition:BioVector? MUG-Lucifer-met 是一種高度專業(yè)化的、經(jīng)過穩(wěn)定轉(zhuǎn)染的人類骨肉瘤 (Osteosarcoma) 細(xì)胞系。該細(xì)胞系源自 MUG-Lucifer 母系，其核心特征是穩(wěn)定表達(dá)熒光素酶 (Luciferase) 報(bào)告基因，并且具有極高的轉(zhuǎn)移 (Metastatic) 潛能。它被設(shè)計(jì)用于腫瘤生物學(xué)研究，特別是通過非侵入性生物發(fā)光成像 (BLI) 技術(shù)在活體動(dòng)物模型中實(shí)時(shí)監(jiān)測(cè)腫瘤的生長(zhǎng)、血管生成以及向遠(yuǎn)端器官（如肺部）的轉(zhuǎn)移過程。

BioVector? MUG-Lucifer-met is a highly specialized, stably transfected Human Osteosarcoma cell line. Derived from the MUG-Lucifer parental line, its core feature is the stable expression of the Luciferase reporter gene, coupled with high metastatic potential. It is designed for cancer research, specifically enabling the real-time monitoring of tumor growth, angiogenesis, and distal metastasis (such as to the lungs) in live animal models through non-invasive Bioluminescence Imaging (BLI).

BioVector? MUG-Lucifer-met 技術(shù)說明書 (Technical Datasheet)

中文版說明書

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? MUG-Lucifer-met 人骨肉瘤細(xì)胞

• 組織來源： 骨 (Bone)

• 標(biāo)記基因： 螢火蟲熒光素酶 (Firefly Luciferase)

• 生長(zhǎng)特性： 貼壁生長(zhǎng)

• 細(xì)胞形態(tài)： 成纖維細(xì)胞樣或多角形

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? RPMI-1640 與 DMEM (1:1) 混合培養(yǎng)基

• 血清添加： 10% BioVector? 優(yōu)質(zhì)胎牛血清 (FBS)

• 篩選抗生素： 含有適量的博來霉素 (Zeocin) 或 嘌呤霉素 (Puromycin)（取決于具體的構(gòu)建載體）以維持熒光素酶的表達(dá)。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% CO2

• 傳代比例： 1:3 至 1:6；建議在細(xì)胞匯合度達(dá)到 80%-90% 時(shí)傳代。

3. 細(xì)胞應(yīng)用

• 活體成像 (In vivo Imaging)： 通過向小鼠注射熒光素底物，實(shí)時(shí)觀察腫瘤轉(zhuǎn)移的動(dòng)態(tài)過程。

• 轉(zhuǎn)移機(jī)制研究： 探索導(dǎo)致骨肉瘤細(xì)胞向肺部轉(zhuǎn)移的分子開關(guān)。

• 藥物評(píng)價(jià)： 定量評(píng)估新型抗癌藥物在抑制腫瘤轉(zhuǎn)移方面的有效性。

4. 注意事項(xiàng)

• 信號(hào)驗(yàn)證： 在進(jìn)行活體實(shí)驗(yàn)前，建議先通過體外熒光素酶活性檢測(cè) (Luciferase Assay) 驗(yàn)證細(xì)胞的信號(hào)強(qiáng)度。

• 生物安全性： 涉及轉(zhuǎn)基因和人源腫瘤細(xì)胞操作，須符合生物安全二級(jí) (BSL-2) 標(biāo)準(zhǔn)。

English Datasheet

1. General Product Information

• Product Name: BioVector? MUG-Lucifer-met Human Osteosarcoma Cell Line

• Tissue Source: Bone

• Reporter Gene: Firefly Luciferase

• Growth Properties: Adherent

• Morphology: Fibroblast-like or polygonal

2. Culture Conditions

• Basal Medium: BioVector? RPMI-1640 and DMEM (1:1) mixture

• Serum Supplement: 10% BioVector? Fetal Bovine Serum (FBS)

• Selection Antibiotic: Maintain with appropriate Zeocin or Puromycin (depending on the specific vector construct) to ensure stable Luciferase expression.

• Incubation: 37 degrees Celsius, 5% CO2

• Subculturing: 1:3 to 1:6 ratio; subculture when cells reach 80%-90% confluence.

3. Applications

• In vivo Imaging: Utilizing Bioluminescence Imaging (BLI) following D-luciferin injection to visualize the dynamic process of tumor metastasis in mice.

• Metastasis Research: Exploring the molecular switches that drive osteosarcoma cells to colonize the lungs.

• Drug Evaluation: Quantitatively assessing the efficacy of novel anti-cancer drugs in inhibiting metastatic progression.

4. Key Usage Notes

• Signal Validation: Before conducting in vivo studies, verify the signal intensity via an in vitro luciferase activity assay to ensure the reporter gene has not been silenced.

• Safety Protocols: As these are genetically modified human tumor cells, all handling must be performed under Biosafety Level 2 (BSL-2) conditions.

Note: For consistent bioluminescence signals, BioVector? recommends the use of its validated Luciferin substrates and high-grade FBS. Periodic STR profiling is suggested to maintain the integrity of the BioVector? MUG-Lucifer-met lineage.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址

http://www.nedfriskphoto.com